Asset Details
Do you wish to reserve the book?
Rosuvastatin-Induced Arrest in Progression of Renal Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Rosuvastatin-Induced Arrest in Progression of Renal Disease
Do you wish to request the book?
Rosuvastatin-Induced Arrest in Progression of Renal Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Rosuvastatin-Induced Arrest in Progression of Renal Disease
2004
Overview
Preclinical and limited clinical data suggest that statins decrease the progressive decline in renal function that occurs in patients with renal disease. Pooled analysis of data obtained from a population of hyperlipidemic patients enrolled in the rosuvastatin (Crestor ® ) clinical development program permitted assessment of its effects on renal function both early and later in the course of treatment. Study participants were initially included in controlled clinical trials that evaluated the lipid-lowering efficacy and safety of rosuvastatin when compared with placebo or other lipid-lowering agents (i.e., atorvastatin, simvastatin, pravastatin, cholestyramine, fenofibrate or extended-release niacin). The median duration of treatment with the various doses of statins in these trials was approximately 8 weeks. Following completion of a controlled clinical trial, patients were permitted to enter an open-label extension trial and received rosuvastatin treatment. These data permitted assessment of renal function in a diverse group of over 10,000 patients who received rosuvastatin in its recommended dose range (5–40 mg) for up to 3.8 years. Mean serum creatinine concentrations were lower when compared with baseline both early and later in the course of rosuvastatin treatment. In contrast, no change in mean serum creatinine was observed with placebo. Mean glomerular filtration rates (GFR) predicted from the Modification of Diet in Renal Disease (MDRD) equation were higher when compared with baseline both early and later in the course of rosuvastatin treatment. No change in GFR was observed in the placebo group. Among patients who received long-term rosuvastatin treatment (≧96 weeks), GFR was unchanged or tended to increase, rather than decrease, when compared with baseline irrespective of age, gender, hypertensive or diabetic status, level of renal function (GFR ≧60 vs. <60 ml/min/1.73 m 2 ) at entry or urine dipstick protein status prior to or during the period of treatment. These findings suggest that rosuvastatin may arrest the progression of renal disease.
Publisher
S. Karger AG
Subject
/ Controlled Clinical Trials as Topic
/ Drug Administration Schedule
/ Female
/ Fluorobenzenes - administration & dosage
/ Fluorobenzenes - pharmacology
/ Heptanoic Acids - administration & dosage
/ Heptanoic Acids - pharmacology
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
/ Hypolipidemic Agents - administration & dosage
/ Hypolipidemic Agents - pharmacology
/ Kidney Diseases - drug therapy
/ Kidney Diseases - physiopathology
/ Male
/ Pravastatin - administration & dosage
/ Pyrimidines - administration & dosage
/ Pyrroles - administration & dosage
/ Simvastatin - administration & dosage
